Kjersti Kirkeby, MD
Endocrinology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: California Pacific Medical Center - Mission Bernal · California Pacific Medical Center- Van Ness Campus · California Pacific Medical Ctr-Davies Campus Hosp · Novato Community Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kirkeby’s office at (415) 600-0110 to ask if they take your plan before you enroll.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
- Novato Community HospitalNovato, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Novato Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 213 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.4 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 25 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.1 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.3 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 627 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,872 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,796 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.92 (0.5 to 5.33) · 505 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 317 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.2 (0.51 to 3.88) · 495 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.93 (0 to 17.29) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 311 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 1,320 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 143 cases | None | Apr 2023 – Mar 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 108 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.9 · 121 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.1 · 150 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 118 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 27 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.5 to 16.5) · 930 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 184 cases | No different | Jan 2024 – Dec 2024 |
What patients said (334 patients answered, 30% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$90,413
Medicare paid this office $90,413 for 306 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 265 | $56,601 | $108 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 97 | $6,530 | $30 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 236 | $6,318 | $14 |
| Diabetes outpatient self-management training services, individual, per 30 minutes | 41 | $5,649 | $50 |
| New patient visit (45+ min) | 29 | $4,376 | $151 |
See all 10 services
| Return visit (30+ min) | 265 | $56,601 | $108 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 97 | $6,530 | $30 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 236 | $6,318 | $14 |
| Diabetes outpatient self-management training services, individual, per 30 minutes | 41 | $5,649 | $50 |
| New patient visit (45+ min) | 29 | $4,376 | $151 |
| Long return visit (40+ min) | 15 | $2,595 | $153 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $2,179 | $70 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,630 | $148 |
| Hemoglobin a1c level | 105 | $1,628 | $10 |
| Blood glucose (sugar) test performed by hand-held instrument | 31 | $138 | $3 |
Who their Medicare patients are
306 Original Medicare patients in 2024. Average age 73 · Under 65 10% · 85 and older 8% · Women 57% · Also on Medicaid 32% · Health risk score 1.77. Above the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 75% · Diabetes 67% · Chronic kidney disease 40% · Coronary heart disease 29% · Depression 28% · Heart failure 22% · Atrial fibrillation 20% · Cancer 19% · COPD 13% · Dementia 11% · Stroke 5%.
The office billed $352,269, Medicare allowed $123,139 and paid $90,413; for 1,668 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 306 | 1,668 | 73 | 1.77 | $352,269 | $90,413 |
| 2023 | 281 | 1,235 | 73 | 1.59 | $326,525 | $88,394 |
| 2022 | 315 | 1,327 | 72 | 1.68 | $332,045 | $92,364 |
| 2021 | 291 | 1,041 | 72 | 1.73 | $283,817 | $84,317 |
| 2020 | 232 | 776 | 71 | 1.98 | $209,437 | $50,811 |
| 2019 | 248 | 1,358 | 71 | 1.79 | $246,143 | $60,010 |
| 2018 | 247 | 866 | 70 | 1.83 | $247,398 | $60,954 |
| 2017 | 232 | 698 | 69 | 1.77 | $213,857 | $56,550 |
| 2016 | 200 | 695 | 69 | 1.83 | $178,776 | $46,477 |
| 2015 | 179 | 601 | 68 | 1.51 | $164,541 | $42,855 |
| 2014 | 153 | 467 | 70 | 1.63 | $129,319 | $34,302 |
| 2013 | 134 | 467 | 68 | 1.77 | $126,351 | $33,340 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Return visit (30+ min) | 233 | $58,103 | $109 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 80 | $6,620 | $30 |
| Diabetes outpatient self-management training services, individual, per 30 minutes | 46 | $5,573 | $48 |
| Long return visit (40+ min) | 25 | $4,968 | $166 |
| New patient visit (45+ min) | 22 | $3,155 | $143 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $2,656 | $72 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,045 | $157 |
| New patient visit (60+ min) | 11 | $1,904 | $173 |
| Hemoglobin a1c level | 104 | $1,799 | $10 |
| Blood glucose (sugar) test performed by hand-held instrument | 35 | $154 | $3 |
2022: 9 services
| Return visit (30+ min) | 267 | $59,482 | $109 |
| Long return visit (40+ min) | 38 | $6,761 | $138 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 84 | $6,140 | $30 |
| Diabetes outpatient self-management training services, individual, per 30 minutes | 43 | $5,088 | $48 |
| New patient visit (60+ min) | 26 | $4,344 | $167 |
| New patient visit (45+ min) | 21 | $3,134 | $149 |
| Hemoglobin a1c level | 129 | $2,025 | $10 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,952 | $177 |
| Blood glucose (sugar) test performed by hand-held instrument | 42 | $181 | $3 |
2021: 8 services
| Return visit (30+ min) | 226 | $48,707 | $112 |
| Long return visit (40+ min) | 75 | $13,415 | $149 |
| New patient visit (60+ min) | 35 | $6,615 | $189 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 67 | $4,651 | $30 |
| Diabetes outpatient self-management training services, individual, per 30 minutes | 24 | $2,480 | $53 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,352 | $168 |
| Hemoglobin a1c level | 100 | $1,544 | $10 |
| Blood glucose (sugar) test performed by hand-held instrument | 36 | $151 | $3 |
2020: 12 services
| Return visit (30+ min) | 186 | $32,698 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,678 | $184 |
| Diabetes outpatient self-management training services, individual, per 30 minutes | 18 | $2,116 | $48 |
| Long return visit (40+ min) | 17 | $2,029 | $107 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 33 | $1,996 | $30 |
| New patient visit (60+ min) | 12 | $1,891 | $158 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,120 | $66 |
| Hemoglobin a1c level | 82 | $1,069 | $10 |
| Telephone medical discussion with physician, 11-20 minutes | 15 | $1,020 | $68 |
| Influenza vaccine split virus, preservative free | 12 | $732 | $61 |
| Administration of influenza virus vaccine | 12 | $247 | $21 |
| Blood glucose (sugar) test performed by hand-held instrument | 32 | $123 | $3 |
2019: 7 services
| Return visit (30+ min) | 207 | $39,519 | $90 |
| New patient visit (60+ min) | 26 | $4,744 | $182 |
| Diabetes outpatient self-management training services, individual, per 30 minutes | 25 | $3,743 | $52 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 35 | $2,365 | $30 |
| Long return visit (40+ min) | 17 | $2,059 | $114 |
| Hemoglobin a1c level | 112 | $1,837 | $11 |
| Blood glucose (sugar) test performed by hand-held instrument | 35 | $138 | $3 |
2018: 8 services
| Return visit (30+ min) | 204 | $39,988 | $89 |
| New patient visit (60+ min) | 33 | $6,126 | $186 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,700 | $180 |
| Long return visit (40+ min) | 18 | $2,428 | $110 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,992 | $64 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 26 | $1,673 | $30 |
| Hemoglobin a1c level | 75 | $1,422 | $12 |
| Blood glucose (sugar) test performed by hand-held instrument | 31 | $122 | $3 |
2017: 7 services
| Return visit (30+ min) | 194 | $38,018 | $90 |
| New patient visit (60+ min) | 22 | $3,989 | $181 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 14 | $2,449 | $163 |
| Long return visit (40+ min) | 16 | $2,133 | $118 |
| Hemoglobin a1c level | 60 | $1,331 | $13 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 19 | $945 | $38 |
| Blood glucose (sugar) test performed by hand-held instrument | 26 | $85 | $3 |
2016: 4 services
| Return visit (30+ min) | 166 | $32,650 | $91 |
| Long return visit (40+ min) | 22 | $3,461 | $112 |
| New patient visit (60+ min) | 16 | $3,037 | $190 |
| Hemoglobin a1c level | 61 | $1,345 | $13 |
2015: 6 services
| Return visit (30+ min) | 146 | $29,504 | $92 |
| New patient visit (45+ min) | 23 | $3,041 | $132 |
| New patient visit (60+ min) | 15 | $2,341 | $156 |
| Long return visit (40+ min) | 13 | $2,277 | $114 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $2,005 | $182 |
| Hemoglobin a1c level | 50 | $829 | $13 |
2014: 4 services
| Return visit (30+ min) | 114 | $22,700 | $90 |
| New patient visit (60+ min) | 14 | $2,545 | $182 |
| New patient visit (45+ min) | 18 | $2,528 | $140 |
| Hemoglobin a1c level | 38 | $862 | $13 |
2013: 5 services
| Return visit (30+ min) | 105 | $19,751 | $92 |
| New patient visit (60+ min) | 20 | $3,119 | $156 |
| Long return visit (40+ min) | 12 | $2,323 | $129 |
| New patient visit (45+ min) | 15 | $2,177 | $145 |
| Hemoglobin a1c level | 39 | $723 | $13 |
Medicaid work
$10,312 in 2024
Medicaid paid $10,312 for 203 billed services this clinician did in 2024, up to 21 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 164 | $10,181 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 39 | $131 |
| 2024 | 203 | 2 | 21 | $10,312 |
| 2023 | 145 | 1 | 24 | $9,398 |
| 2022 | 189 | 2 | 28 | $4,418 |
| 2021 | 165 | 1 | 26 | $4,179 |
| 2020 | 97 | 1 | 21 | $1,647 |
| 2019 | 127 | 1 | 16 | $2,642 |
| 2018 | 71 | 1 | 17 | $1,002 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 145 | $9,398 |
2022
| Return visit (30+ min) | 176 | $4,375 |
| Hemoglobin A1C level | 13 | $43 |
2021
| Return visit (30+ min) | 165 | $4,179 |
2020
| Return visit (30+ min) | 97 | $1,647 |
2019
| Return visit (30+ min) | 127 | $2,642 |
2018
| Return visit (30+ min) | 71 | $1,002 |
Drugs they prescribed that Part D paid
$2,092,856
Pharmacies billed $2,092,856 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 3,915) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
1,576 generic and 2,050 brand-name prescriptions · $2,092,856 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ozempic | 461 | $692,550 | $1,502 |
| Jardiance | 255 | $350,251 | $1,374 |
| Mounjaro | 177 | $219,054 | $1,238 |
| Trulicity | 61 | $95,829 | $1,571 |
| Tresiba Flextouch U-200 | 47 | $68,304 | $1,453 |
See all 48 drugs
| Ozempic | 461 | $692,550 | $1,502 |
| Jardiance | 255 | $350,251 | $1,374 |
| Mounjaro | 177 | $219,054 | $1,238 |
| Trulicity | 61 | $95,829 | $1,571 |
| Tresiba Flextouch U-200 | 47 | $68,304 | $1,453 |
| Tresiba Flextouch U-100 | 101 | $60,072 | $595 |
| Rybelsus | 40 | $55,161 | $1,379 |
| Januvia | 40 | $51,797 | $1,295 |
| Tradjenta | 41 | $46,208 | $1,127 |
| Humalog Kwikpen U-200 | 14 | $42,048 | $3,003 |
| Basaglar Kwikpen U-100 | 98 | $40,531 | $414 |
| Fiasp Flextouch | 45 | $31,775 | $706 |
| Farxiga | 26 | $25,230 | $970 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | 17 | $25,127 | $1,478 |
| Nano 2nd Gen Pen Needle | 152 | $17,474 | $115 |
| Humalog Kwikpen U-100 | 37 | $12,639 | $342 |
| Vascepa | 18 | $12,571 | $698 |
| Lantus Solostar | 82 | $11,749 | $143 |
| Insulin Lispro Kwikpen U-100 | 37 | $10,791 | $292 |
| Synthroid | 74 | $6,668 | $90 |
| Novolog | 34 | $5,897 | $173 |
| Ultra-Fine Short Pen Needle | 42 | $5,784 | $138 |
| Humalog Mix 75-25 Kwikpen | 17 | $4,619 | $272 |
| Novolog Flexpen | 26 | $4,577 | $176 |
| Metformin Hcl Er | 251 | $3,880 | $15 |
| Humalog Junior Kwikpen | 21 | $3,579 | $170 |
| Levothyroxine | 165 | $3,053 | $19 |
| Ultra-Fine Mini Pen Needle | 23 | $2,990 | $130 |
| Atorvastatin | 237 | $2,781 | $12 |
| Insulin Lispro Protamine Mix | 13 | $2,736 | $210 |
| Metformin | 147 | $2,120 | $14 |
| Ultra-Fine Nano Pen Needle | 13 | $1,962 | $151 |
| Glipizide | 106 | $1,578 | $15 |
| Novolog Mix 70-30 | 11 | $1,222 | $111 |
| Rosuvastatin | 58 | $1,208 | $21 |
| Hydrocortisone | 25 | $1,090 | $44 |
| Glipizide Er | 73 | $968 | $13 |
| Pioglitazone | 62 | $703 | $11 |
| Losartan | 82 | $699 | $9 |
| Amlodipine Besylate | 71 | $692 | $10 |
| Pravastatin | 33 | $514 | $16 |
| Alendronate | 42 | $415 | $10 |
| Lisinopril | 67 | $324 | $5 |
| Methimazole | 47 | $310 | $7 |
| Metoprolol | 12 | $243 | $20 |
| Cytomel | 12 | $133 | $11 |
| Hydrochlorothiazide | 17 | $63 | $4 |
| Glimepiride | 11 | $43 | $4 |
Year by year
| 2024 | 3,915 | 352 | 0% (0) | 52% | $2,092,856 |
| 2023 | 4,023 | 330 | 0% (0) | 50% | $2,464,586 |
| 2022 | 3,560 | 306 | 0% (0) | 50% | $2,112,828 |
| 2021 | 3,262 | 285 | 0% (0) | 51% | $1,853,391 |
| 2020 | 2,974 | 265 | 0% (0) | 49% | $1,452,668 |
| 2019 | 2,956 | 270 | 0% (0) | 51% | $1,363,886 |
| 2018 | 2,691 | 248 | 0% (0) | 48% | $1,000,410 |
| 2017 | 2,492 | 217 | 0% (0) | 47% | $837,943 |
| 2016 | 2,061 | 182 | None | 48% | $585,035 |
| 2015 | 1,831 | 165 | 0% (0) | 53% | $481,586 |
| 2014 | 1,539 | 142 | None | 54% | $359,366 |
| 2013 | 1,228 | 131 | 0% (0) | 54% | $212,223 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 49 drugs
| Ozempic | 462 | $722,734 | $1,564 |
| Jardiance | 278 | $388,821 | $1,399 |
| Trulicity | 104 | $162,914 | $1,566 |
| Novolog Flexpen | 69 | $95,673 | $1,387 |
| Rybelsus | 44 | $80,444 | $1,828 |
| Lantus Solostar | 92 | $72,346 | $786 |
| Januvia | 66 | $68,725 | $1,041 |
| Tresiba Flextouch U-100 | 96 | $67,446 | $703 |
| Humalog Kwikpen U-100 | 62 | $65,882 | $1,063 |
| Tresiba Flextouch U-200 | 43 | $62,770 | $1,460 |
| Mounjaro | 41 | $56,521 | $1,379 |
| Humalog Kwikpen U-200 | 13 | $49,449 | $3,804 |
| Basaglar Kwikpen U-100 | 76 | $47,435 | $624 |
| Tradjenta | 32 | $41,012 | $1,282 |
| Novolog Mix 70-30 Flexpen | 32 | $37,822 | $1,182 |
| Farxiga | 24 | $36,919 | $1,538 |
| Humalog Mix 75-25 Kwikpen | 20 | $21,816 | $1,091 |
| Novolog | 24 | $21,505 | $896 |
| Omnipod 5 G6 Pods (Gen 5) | 16 | $18,597 | $1,162 |
| Nano 2nd Gen Pen Needle | 154 | $16,232 | $105 |
| Vascepa | 12 | $13,025 | $1,085 |
| Fiasp Flextouch | 19 | $12,072 | $635 |
| Levemir Flexpen | 11 | $11,303 | $1,028 |
| Insulin Lispro Kwikpen U-100 | 25 | $9,010 | $360 |
| Synthroid | 63 | $6,803 | $108 |
| Metformin Hcl Er | 286 | $6,733 | $24 |
| Ultra-Fine Short Pen Needle | 46 | $6,414 | $139 |
| Humalog Junior Kwikpen | 11 | $6,203 | $564 |
| Icosapent Ethyl | 15 | $5,032 | $335 |
| Levemir | 12 | $5,029 | $419 |
| Ultra-Fine Mini Pen Needle | 30 | $3,849 | $128 |
| Levothyroxine | 183 | $3,804 | $21 |
| Atorvastatin | 261 | $3,758 | $14 |
| Metformin | 181 | $3,531 | $20 |
| Hydrocortisone | 29 | $2,645 | $91 |
| Glipizide Er | 94 | $2,410 | $26 |
| Rosuvastatin | 38 | $1,715 | $45 |
| Ultra-Fine Nano Pen Needle | 12 | $1,693 | $141 |
| Glipizide | 100 | $1,663 | $17 |
| Pioglitazone | 56 | $1,259 | $22 |
| Losartan | 78 | $1,193 | $15 |
| Droplet Pen Needle | 16 | $1,013 | $63 |
| Amlodipine Besylate | 67 | $917 | $14 |
| Methimazole | 51 | $814 | $16 |
| Lisinopril | 56 | $574 | $10 |
| Pravastatin | 32 | $515 | $16 |
| Alendronate | 46 | $512 | $11 |
| Simvastatin | 14 | $369 | $26 |
| Olmesartan Medoxomil | 11 | $362 | $33 |
2022: 51 drugs
| Ozempic | 369 | $599,468 | $1,625 |
| Jardiance | 284 | $359,516 | $1,266 |
| Trulicity | 131 | $195,470 | $1,492 |
| Humalog Kwikpen U-200 | 20 | $86,800 | $4,340 |
| Novolog Flexpen | 68 | $82,534 | $1,214 |
| Lantus Solostar | 95 | $77,892 | $820 |
| Tresiba Flextouch U-200 | 46 | $73,760 | $1,603 |
| Januvia | 67 | $68,735 | $1,026 |
| Rybelsus | 36 | $51,500 | $1,431 |
| Tresiba Flextouch U-100 | 69 | $50,463 | $731 |
| Humalog Kwikpen U-100 | 36 | $49,794 | $1,383 |
| Tradjenta | 39 | $46,077 | $1,181 |
| Basaglar Kwikpen U-100 | 64 | $31,355 | $490 |
| Novolog Mix 70-30 Flexpen | 15 | $23,461 | $1,564 |
| Levemir Flextouch | 20 | $16,483 | $824 |
| Victoza 3-Pak | 11 | $14,311 | $1,301 |
| Novolog Penfill | 15 | $12,275 | $818 |
| Nano 2nd Gen Pen Needle | 121 | $12,250 | $101 |
| Farxiga | 11 | $11,550 | $1,050 |
| Gvoke Hypopen 2-Pack | 15 | $10,141 | $676 |
| Toujeo Solostar | 11 | $9,193 | $836 |
| Glyxambi | 12 | $7,211 | $601 |
| Insulin Lispro Kwikpen U-100 | 22 | $6,812 | $310 |
| Onglyza | 12 | $6,028 | $502 |
| Synthroid | 48 | $5,851 | $122 |
| Ultra-Fine Short Pen Needle | 39 | $4,819 | $124 |
| Metformin Hcl Er | 252 | $4,281 | $17 |
| Levothyroxine | 180 | $3,592 | $20 |
| Atorvastatin | 253 | $3,258 | $13 |
| Icosapent Ethyl | 12 | $3,239 | $270 |
| Metformin | 160 | $2,329 | $15 |
| Hydrocortisone | 23 | $2,168 | $94 |
| Glipizide Er | 94 | $2,149 | $23 |
| Ultra-Fine Mini Pen Needle | 19 | $2,117 | $111 |
| Ultra-Fine Nano Pen Needle | 19 | $2,076 | $109 |
| Glipizide | 103 | $2,029 | $20 |
| Rosuvastatin | 31 | $1,556 | $50 |
| Droplet Pen Needle | 17 | $1,186 | $70 |
| Losartan | 79 | $984 | $12 |
| Amlodipine Besylate | 51 | $747 | $15 |
| Pioglitazone | 41 | $636 | $16 |
| Simvastatin | 17 | $567 | $33 |
| Lisinopril | 44 | $507 | $12 |
| Metoprolol | 17 | $482 | $28 |
| Alendronate | 51 | $471 | $9 |
| Spironolactone | 11 | $421 | $38 |
| Chlorthalidone | 11 | $341 | $31 |
| Methimazole | 24 | $311 | $13 |
| Pravastatin | 15 | $276 | $18 |
| Gabapentin | 17 | $276 | $16 |
| Hydrochlorothiazide | 14 | $97 | $7 |
2021: 50 drugs
| Ozempic | 205 | $339,189 | $1,655 |
| Jardiance | 276 | $281,640 | $1,020 |
| Trulicity | 153 | $246,215 | $1,609 |
| Tresiba Flextouch U-200 | 57 | $125,031 | $2,194 |
| Lantus Solostar | 112 | $89,371 | $798 |
| Novolog Flexpen | 88 | $85,754 | $974 |
| Humalog Kwikpen U-200 | 21 | $77,479 | $3,689 |
| Victoza 3-Pak | 38 | $68,024 | $1,790 |
| Humalog Kwikpen U-100 | 48 | $54,047 | $1,126 |
| Tresiba Flextouch U-100 | 68 | $51,646 | $759 |
| Januvia | 38 | $38,939 | $1,025 |
| Tradjenta | 49 | $35,499 | $724 |
| Rybelsus | 24 | $32,131 | $1,339 |
| Basaglar Kwikpen U-100 | 66 | $31,721 | $481 |
| Levemir Flextouch | 33 | $22,522 | $682 |
| Novolog Mix 70-30 Flexpen | 11 | $18,281 | $1,662 |
| Toujeo Solostar | 12 | $13,504 | $1,125 |
| Insulin Lispro Kwikpen U-100 | 20 | $13,397 | $670 |
| Nano 2nd Gen Pen Needle | 141 | $13,081 | $93 |
| Gvoke Hypopen 2-Pack | 17 | $12,545 | $738 |
| Novolog Penfill | 12 | $10,226 | $852 |
| Vascepa | 12 | $7,177 | $598 |
| Tirosint | 20 | $6,332 | $317 |
| Onglyza | 12 | $5,852 | $488 |
| Synthroid | 53 | $5,368 | $101 |
| Atorvastatin | 243 | $3,702 | $15 |
| Levothyroxine | 156 | $3,275 | $21 |
| Metformin Hcl Er | 186 | $3,115 | $17 |
| Ultra-Fine Short Pen Needle | 24 | $2,704 | $113 |
| Glipizide Er | 79 | $2,171 | $27 |
| Ultra-Fine Nano Pen Needle | 19 | $2,144 | $113 |
| Ultra-Fine Mini Pen Needle | 19 | $1,881 | $99 |
| Metformin | 142 | $1,726 | $12 |
| Glipizide | 98 | $1,559 | $16 |
| Droplet Pen Needle | 27 | $1,502 | $56 |
| Hydrocortisone | 22 | $884 | $40 |
| Rosuvastatin | 40 | $869 | $22 |
| Losartan | 53 | $815 | $15 |
| Liothyronine | 11 | $712 | $65 |
| Amlodipine Besylate | 63 | $549 | $9 |
| Alendronate | 47 | $455 | $10 |
| Pioglitazone | 22 | $345 | $16 |
| Metoprolol | 13 | $339 | $26 |
| Methimazole | 25 | $297 | $12 |
| Lisinopril | 44 | $271 | $6 |
| Fenofibrate | 11 | $267 | $24 |
| Pravastatin | 11 | $199 | $18 |
| Simvastatin | 13 | $196 | $15 |
| Gabapentin | 11 | $65 | $6 |
| Hydrochlorothiazide | 11 | $25 | $2 |
2020: 50 drugs
| Jardiance | 179 | $171,380 | $957 |
| Trulicity | 104 | $144,080 | $1,385 |
| Novolog Flexpen | 94 | $117,484 | $1,250 |
| Ozempic | 81 | $113,061 | $1,396 |
| Victoza 3-Pak | 67 | $110,863 | $1,655 |
| Tresiba Flextouch U-200 | 50 | $107,295 | $2,146 |
| Lantus Solostar | 112 | $77,393 | $691 |
| Humalog Kwikpen U-100 | 57 | $74,435 | $1,306 |
| Humalog Kwikpen U-200 | 23 | $65,480 | $2,847 |
| Januvia | 45 | $39,930 | $887 |
| Tresiba Flextouch U-100 | 58 | $36,942 | $637 |
| Basaglar Kwikpen U-100 | 65 | $32,947 | $507 |
| Novolog | 33 | $28,328 | $858 |
| Tradjenta | 41 | $26,825 | $654 |
| Levemir Flextouch | 37 | $24,775 | $670 |
| Novolog Mix 70-30 Flexpen | 12 | $23,250 | $1,938 |
| Janumet Xr | 13 | $16,060 | $1,235 |
| Toujeo Solostar | 14 | $16,025 | $1,145 |
| Humalog | 12 | $14,722 | $1,227 |
| Insulin Lispro Kwikpen U-100 | 24 | $13,379 | $557 |
| Onglyza | 23 | $10,621 | $462 |
| Ultra-Fine Nano Pen Needle | 124 | $10,207 | $82 |
| Baqsimi | 17 | $9,736 | $573 |
| Lantus | 13 | $8,614 | $663 |
| Synthroid | 59 | $5,728 | $97 |
| Tirosint | 22 | $5,383 | $245 |
| Cinacalcet | 13 | $4,492 | $346 |
| Atorvastatin | 213 | $4,147 | $19 |
| Ultra-Fine Mini Pen Needle | 37 | $4,053 | $110 |
| Nano 2nd Gen Pen Needle | 44 | $3,888 | $88 |
| Metformin Hcl Er | 187 | $3,778 | $20 |
| Levothyroxine | 135 | $3,285 | $24 |
| Glipizide Er | 87 | $2,520 | $29 |
| Ultra-Fine Short Pen Needle | 21 | $2,398 | $114 |
| Metformin | 139 | $1,587 | $11 |
| Glipizide | 104 | $1,481 | $14 |
| Losartan | 44 | $967 | $22 |
| Rosuvastatin | 22 | $887 | $40 |
| Pravastatin | 19 | $636 | $33 |
| Spironolactone | 18 | $516 | $29 |
| Droplet Pen Needle | 24 | $425 | $18 |
| Alendronate | 44 | $383 | $9 |
| Hydrocortisone | 15 | $374 | $25 |
| Metoprolol | 17 | $338 | $20 |
| Methimazole | 24 | $333 | $14 |
| Amlodipine Besylate | 43 | $328 | $8 |
| Pioglitazone | 13 | $260 | $20 |
| Simvastatin | 23 | $231 | $10 |
| Lisinopril | 41 | $174 | $4 |
| Hydrochlorothiazide | 12 | $126 | $11 |
2019: 47 drugs
| Novolog Flexpen | 126 | $143,912 | $1,142 |
| Trulicity | 118 | $133,296 | $1,130 |
| Victoza 3-Pak | 68 | $112,375 | $1,653 |
| Tresiba Flextouch U-200 | 75 | $104,452 | $1,393 |
| Jardiance | 129 | $90,420 | $701 |
| Humalog Kwikpen U-100 | 73 | $90,216 | $1,236 |
| Humalog Kwikpen U-200 | 32 | $86,371 | $2,699 |
| Lantus Solostar | 130 | $86,133 | $663 |
| Ozempic | 56 | $64,405 | $1,150 |
| Januvia | 50 | $50,682 | $1,014 |
| Levemir Flextouch | 51 | $36,491 | $716 |
| Novolog Mix 70-30 Flexpen | 19 | $29,038 | $1,528 |
| Tresiba Flextouch U-100 | 45 | $28,812 | $640 |
| Basaglar Kwikpen U-100 | 72 | $28,648 | $398 |
| Humalog | 30 | $28,235 | $941 |
| Tradjenta | 32 | $21,534 | $673 |
| Novolog | 32 | $21,188 | $662 |
| Toujeo Solostar | 11 | $19,410 | $1,765 |
| Janumet Xr | 17 | $16,654 | $980 |
| Ultra-Fine Nano Pen Needle | 142 | $10,854 | $76 |
| Onglyza | 23 | $10,235 | $445 |
| Synthroid | 60 | $5,466 | $91 |
| Atorvastatin | 193 | $3,985 | $21 |
| Levothyroxine | 154 | $3,826 | $25 |
| Ultra-Fine Mini Pen Needle | 43 | $3,756 | $87 |
| Tirosint | 17 | $3,505 | $206 |
| Metformin Hcl Er | 172 | $3,228 | $19 |
| Ultra-Fine Short Pen Needle | 23 | $2,476 | $108 |
| Cytomel | 14 | $2,341 | $167 |
| Glipizide Er | 50 | $1,946 | $39 |
| Glipizide | 133 | $1,910 | $14 |
| Metformin | 137 | $1,571 | $11 |
| Liothyronine | 22 | $1,023 | $47 |
| Metoprolol | 26 | $924 | $36 |
| Insulin | 22 | $857 | $39 |
| Rosuvastatin | 21 | $799 | $38 |
| Pioglitazone | 19 | $655 | $34 |
| Pravastatin | 22 | $512 | $23 |
| Spironolactone | 15 | $451 | $30 |
| Losartan | 45 | $442 | $10 |
| Alendronate | 45 | $328 | $7 |
| Amlodipine Besylate | 35 | $259 | $7 |
| Methimazole | 24 | $231 | $10 |
| Lisinopril | 29 | $216 | $7 |
| Droplet Pen Needle | 13 | $202 | $16 |
| Simvastatin | 14 | $122 | $9 |
| Ramipril | 12 | $83 | $7 |
2018: 44 drugs
| Victoza 3-Pak | 96 | $130,327 | $1,358 |
| Novolog Flexpen | 114 | $121,566 | $1,066 |
| Humalog Kwikpen U-100 | 83 | $93,766 | $1,130 |
| Tresiba Flextouch U-200 | 79 | $82,823 | $1,048 |
| Lantus Solostar | 115 | $67,466 | $587 |
| Trulicity | 39 | $44,904 | $1,151 |
| Januvia | 40 | $39,251 | $981 |
| Tradjenta | 47 | $34,276 | $729 |
| Jardiance | 54 | $32,291 | $598 |
| Basaglar Kwikpen U-100 | 79 | $29,754 | $377 |
| Humalog Kwikpen U-200 | 14 | $29,314 | $2,094 |
| Tresiba Flextouch U-100 | 37 | $24,752 | $669 |
| Levemir Flextouch | 37 | $23,403 | $633 |
| Humalog | 31 | $20,118 | $649 |
| Novolog Mix 70-30 Flexpen | 11 | $16,891 | $1,536 |
| Janumet Xr | 14 | $16,472 | $1,177 |
| Novolog | 16 | $15,359 | $960 |
| Onglyza | 22 | $9,569 | $435 |
| Ultra-Fine Nano Pen Needle | 129 | $8,580 | $67 |
| Levothyroxine | 183 | $4,427 | $24 |
| Synthroid | 54 | $4,325 | $80 |
| Cytomel | 23 | $3,771 | $164 |
| Atorvastatin | 179 | $3,678 | $21 |
| Tirosint | 13 | $3,120 | $240 |
| Ultra-Fine Mini Pen Needle | 32 | $2,932 | $92 |
| Ultra-Fine Short Pen Needle | 27 | $2,246 | $83 |
| Metformin Hcl Er | 120 | $1,999 | $17 |
| Metformin | 114 | $1,316 | $12 |
| Glipizide Er | 50 | $1,171 | $23 |
| Glipizide | 123 | $1,155 | $9 |
| Metoprolol | 27 | $1,120 | $41 |
| Liothyronine | 19 | $771 | $41 |
| Pravastatin | 25 | $730 | $29 |
| Insulin | 18 | $558 | $31 |
| Methimazole | 32 | $497 | $16 |
| Pioglitazone | 21 | $452 | $22 |
| Losartan | 47 | $395 | $8 |
| Alendronate | 46 | $376 | $8 |
| Spironolactone | 13 | $351 | $27 |
| Hydrocortisone | 13 | $323 | $25 |
| Lisinopril | 59 | $274 | $5 |
| Amlodipine Besylate | 43 | $267 | $6 |
| Ramipril | 16 | $244 | $15 |
| Gabapentin | 14 | $68 | $5 |
2017: 49 drugs
| Tresiba Flextouch U-200 | 88 | $102,414 | $1,164 |
| Novolog Flexpen | 90 | $95,041 | $1,056 |
| Victoza 3-Pak | 73 | $74,356 | $1,019 |
| Lantus Solostar | 154 | $74,000 | $481 |
| Humalog Kwikpen U-100 | 66 | $63,127 | $956 |
| Trulicity | 46 | $39,531 | $859 |
| Apidra Solostar | 19 | $37,249 | $1,960 |
| Januvia | 34 | $32,296 | $950 |
| Levemir Flextouch | 35 | $28,128 | $804 |
| Tradjenta | 49 | $27,845 | $568 |
| Novolog Mix 70-30 Flexpen | 15 | $22,941 | $1,529 |
| Humalog Kwikpen U-200 | 14 | $21,422 | $1,530 |
| Tresiba Flextouch U-100 | 26 | $16,154 | $621 |
| Novolog | 21 | $14,376 | $685 |
| Humalog | 23 | $13,112 | $570 |
| Jardiance | 21 | $12,462 | $593 |
| Lantus | 13 | $11,255 | $866 |
| Invokana | 15 | $7,882 | $525 |
| Onglyza | 20 | $7,729 | $386 |
| Ultra-Fine Nano Pen Needle | 103 | $6,539 | $63 |
| Tirosint | 19 | $5,022 | $264 |
| Synthroid | 57 | $3,780 | $66 |
| Levothyroxine | 168 | $3,768 | $22 |
| Atorvastatin | 183 | $3,666 | $20 |
| Vgo 40 | 11 | $3,483 | $317 |
| Cytomel | 19 | $2,638 | $139 |
| Ultra-Fine Short Pen Needle | 32 | $2,270 | $71 |
| Ultra-Fine Mini Pen Needle | 22 | $1,793 | $81 |
| Glipizide Er | 60 | $1,636 | $27 |
| Bd Ultra-Fine Pen Needle | 21 | $1,609 | $77 |
| Metformin | 108 | $1,297 | $12 |
| Metformin Hcl Er | 80 | $1,018 | $13 |
| Glipizide | 124 | $874 | $7 |
| Alendronate | 77 | $747 | $10 |
| Liothyronine | 21 | $741 | $35 |
| Armour Thyroid | 12 | $698 | $58 |
| Insulin | 14 | $608 | $43 |
| Metoprolol | 11 | $546 | $50 |
| Losartan | 60 | $435 | $7 |
| Hydrocortisone | 13 | $404 | $31 |
| Pravastatin | 17 | $388 | $23 |
| Glipizide Xl | 17 | $342 | $20 |
| Amlodipine Besylate | 53 | $263 | $5 |
| Lisinopril | 46 | $195 | $4 |
| Gabapentin | 13 | $164 | $13 |
| Methimazole | 15 | $120 | $8 |
| Ramipril | 13 | $73 | $6 |
| Simvastatin | 23 | $65 | $3 |
| Atenolol | 26 | $44 | $2 |
2016: 40 drugs
| Lantus Solostar | 141 | $72,225 | $512 |
| Novolog Flexpen | 63 | $65,318 | $1,037 |
| Victoza 3-Pak | 66 | $53,219 | $806 |
| Humalog Kwikpen U-100 | 56 | $38,465 | $687 |
| Tresiba Flextouch U-200 | 36 | $34,379 | $955 |
| Levemir Flextouch | 45 | $31,553 | $701 |
| Tradjenta | 56 | $27,040 | $483 |
| Trulicity | 31 | $27,014 | $871 |
| Januvia | 38 | $24,672 | $649 |
| Humalog Mix 75-25 Kwikpen | 21 | $14,614 | $696 |
| Bd Ultra-Fine Pen Needle | 193 | $12,038 | $62 |
| Lantus | 23 | $11,979 | $521 |
| Apidra Solostar | 18 | $11,579 | $643 |
| Onglyza | 21 | $8,412 | $401 |
| Bydureon | 11 | $7,956 | $723 |
| Humalog | 14 | $7,019 | $501 |
| Novolog | 13 | $6,838 | $526 |
| Invokana | 14 | $5,203 | $372 |
| Levemir | 11 | $4,675 | $425 |
| Tirosint | 19 | $3,931 | $207 |
| Synthroid | 59 | $3,505 | $59 |
| Levothyroxine | 155 | $3,115 | $20 |
| Cytomel | 19 | $2,766 | $146 |
| Atorvastatin | 100 | $1,922 | $19 |
| Metformin Hcl Er | 91 | $1,248 | $14 |
| Glipizide Er | 51 | $1,005 | $20 |
| Glipizide | 122 | $843 | $7 |
| Metoprolol | 12 | $610 | $51 |
| Metformin | 38 | $544 | $14 |
| Liothyronine | 22 | $500 | $23 |
| Alendronate | 56 | $449 | $8 |
| Glipizide Xl | 15 | $427 | $28 |
| Losartan | 43 | $383 | $9 |
| Hydrocortisone | 12 | $352 | $29 |
| Amlodipine Besylate | 41 | $341 | $8 |
| Ramipril | 15 | $336 | $22 |
| Atenolol | 33 | $225 | $7 |
| Methimazole | 16 | $168 | $11 |
| Simvastatin | 15 | $101 | $7 |
| Lisinopril | 17 | $63 | $4 |
2015: 32 drugs
| Novolog Flexpen | 99 | $84,061 | $849 |
| Lantus Solostar | 122 | $65,708 | $539 |
| Tradjenta | 81 | $32,166 | $397 |
| Humalog Kwikpen U-100 | 47 | $30,341 | $646 |
| Levemir Flextouch | 57 | $28,998 | $509 |
| Januvia | 35 | $23,467 | $670 |
| Victoza 3-Pak | 33 | $22,477 | $681 |
| Invokana | 33 | $16,613 | $503 |
| Lantus | 35 | $15,391 | $440 |
| Novolog | 29 | $13,658 | $471 |
| Bd Ultra-Fine Pen Needle | 137 | $7,476 | $55 |
| Bydureon | 11 | $6,474 | $589 |
| Humalog Mix 75-25 Kwikpen | 13 | $4,703 | $362 |
| Levemir | 11 | $3,683 | $335 |
| Synthroid | 55 | $3,128 | $57 |
| Tirosint | 20 | $3,014 | $151 |
| Levothyroxine | 128 | $2,941 | $23 |
| Metformin Hcl Er | 74 | $1,954 | $26 |
| Atorvastatin | 63 | $1,060 | $17 |
| Glipizide Xl | 42 | $920 | $22 |
| Glipizide Er | 53 | $799 | $15 |
| Glipizide | 89 | $618 | $7 |
| Metformin | 59 | $569 | $10 |
| Hydrocortisone | 14 | $548 | $39 |
| Alendronate | 58 | $473 | $8 |
| Lisinopril | 32 | $258 | $8 |
| Insulin | 14 | $235 | $17 |
| Losartan | 35 | $200 | $6 |
| Amlodipine Besylate | 31 | $157 | $5 |
| Methimazole | 16 | $144 | $9 |
| Atenolol | 24 | $88 | $4 |
| Losartan-Hydrochlorothiazide | 11 | $55 | $5 |
2014: 35 drugs
| Lantus Solostar | 140 | $68,884 | $492 |
| Novolog Flexpen | 95 | $59,518 | $627 |
| Humalog | 62 | $29,433 | $475 |
| Januvia | 38 | $24,263 | $639 |
| Bydureon | 32 | $19,418 | $607 |
| Victoza 3-Pak | 29 | $16,643 | $574 |
| Lantus | 39 | $16,048 | $411 |
| Tradjenta | 30 | $15,148 | $505 |
| Apidra Solostar | 17 | $10,842 | $638 |
| Bd Ultra-Fine Pen Needle | 144 | $7,219 | $50 |
| Levemir Flexpen | 16 | $7,085 | $443 |
| Humalog Mix 75-25 | 14 | $5,749 | $411 |
| Novolog | 11 | $5,651 | $514 |
| Levemir | 15 | $4,246 | $283 |
| Apidra | 13 | $3,788 | $291 |
| Synthroid | 77 | $3,709 | $48 |
| Tirosint | 24 | $3,024 | $126 |
| Levothyroxine | 75 | $1,486 | $20 |
| Atorvastatin | 54 | $1,098 | $20 |
| Glipizide Er | 33 | $821 | $25 |
| Glipizide Xl | 30 | $807 | $27 |
| Insulin | 17 | $775 | $46 |
| Metformin Hcl Er | 35 | $712 | $20 |
| Metformin | 70 | $662 | $9 |
| Liothyronine | 12 | $535 | $45 |
| Glipizide | 56 | $474 | $8 |
| Hydrocortisone | 17 | $430 | $25 |
| Alendronate | 39 | $369 | $9 |
| Insulin | 19 | $324 | $17 |
| Losartan | 13 | $259 | $20 |
| Lisinopril | 30 | $221 | $7 |
| Methimazole | 17 | $204 | $12 |
| Amlodipine Besylate | 27 | $164 | $6 |
| Simvastatin | 12 | $149 | $12 |
| Atenolol | 20 | $87 | $4 |
2013: 27 drugs
| Lantus Solostar | 103 | $31,990 | $311 |
| Novolog Flexpen | 46 | $24,753 | $538 |
| Humalog | 50 | $16,269 | $325 |
| Bydureon | 36 | $15,451 | $429 |
| Januvia | 30 | $12,014 | $400 |
| Lantus | 45 | $11,139 | $248 |
| Tradjenta | 22 | $9,104 | $414 |
| Levemir Flexpen | 19 | $7,520 | $396 |
| Victoza 3-Pak | 13 | $6,436 | $495 |
| Humalog Mix 75-25 | 17 | $5,950 | $350 |
| Bd Ultra-Fine Pen Needle | 115 | $5,406 | $47 |
| Synthroid | 92 | $2,919 | $32 |
| Atorvastatin | 37 | $1,279 | $35 |
| Levothyroxine | 74 | $1,038 | $14 |
| Cytomel | 11 | $994 | $90 |
| Glipizide Er | 36 | $912 | $25 |
| Metformin | 71 | $852 | $12 |
| Liothyronine | 17 | $763 | $45 |
| Glipizide | 31 | $387 | $12 |
| Alendronate | 30 | $374 | $12 |
| Amlodipine Besylate | 36 | $266 | $7 |
| Glipizide Xl | 11 | $260 | $24 |
| Lisinopril | 27 | $217 | $8 |
| Insulin | 11 | $214 | $19 |
| Levoxyl | 15 | $190 | $13 |
| Atenolol | 19 | $102 | $5 |
| Simvastatin | 13 | $96 | $7 |
Money from drug and device companies
$44 in 2024
| 2024 | 2 | 2 | None | $44 |
| 2023 | 2 | 2 | None | $84 |
| 2022 | 2 | 3 | None | $88 |
| 2021 | 1 | 1 | None | $28 |
| 2019 | 4 | 5 | None | $106 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Tandem Diabetes Care | T:Slim X2 Insulin Pump With Control-Iq | $23 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $21 | 1 payment
|
See all 2 published payments
| Dexcom | Meals · 2024-10-08 | Dexcom G6 Transmitter | $21 |
| Tandem Diabetes Care | Meals · 2024-03-17 | T:Slim X2 Insulin Pump With Control-Iq | $23 |
See earlier years (2023, 2022, 2021, 2019)
2023: $84
| Medtronic | Minimed 780g | $61 | 1 payment
|
| Beta Bionics | Ilet Bionic Pancreas | $23 | 1 payment
|
2022: $88
| Horizon Therapeutics plc | Tepezza | $53 | 1 payment
|
| Insulet | Omnipod | $35 | 2 payments
|
2021: $28
| LifeScan | Onetouch Verio Reflect | $28 | 1 payment
|
2019: $106
| Insulet | Omnipod | $42 | 2 payments
|
| Lilly USA | Baqsimi | $24 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $22 | 1 payment
|
| Abbott Laboratories | Freestyle Libre Pro | $19 | 1 payment
|
Professional record
- NPI
- 1811182454
- Licence
- CA 837087
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2007-09-06
- NPI last updated
- 2021-04-28
- NPI record certified
- 2021-04-27
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1580 Valencia St Ste 802, San Francisco, CA, 94110 · 300 Pasteur Dr, Stanford, CA, 94305